Sanofi SA's Fiscal Year is From January To December - All Figures are in EUR, Billions.
The item "Depreciation-and-Amortization-Expense" stands at 1.45 Billion Euros for the trailing twelve months (TTM) period ending 09/30/2025, the lowest value since 09/30/2021.
Sanofi SA's third quarter result of 0.461 Billion EUR for the item "Depreciation and Amortization Expense" represents an increase of 21.96 percent compared to it's second quarter result.
Also, Sanofi SA's third quarter result of 0.461 Billion EUR for the item "Depreciation and Amortization Expense" represents a decrease of -3.76 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), Sanofi SA's third quarter result of 1.45 Billion EUR for the item "Depreciation and Amortization Expense" represents a decrease of -1.23 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes a decrease of -31.58 percent compared to the value the year prior.
The 1 year change in percent is -31.58.
The 3 year change in percent is -19.16.
The 5 year change in percent is 63.87.
The 10 year change in percent is -54.88.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Depreciation and Amortization Expense | 905,699,262,464.00 |
![]() | Johnson & Johnson - Depreciation and Amortization Expense | 486,508,953,600.00 |
![]() | AbbVie Inc - Depreciation and Amortization Expense | 399,570,305,024.00 |
![]() | Roche Holding AG - Depreciation and Amortization Expense | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Depreciation and Amortization Expense | 280,205,508,085.11 |